Table 3.
Study year | Method | Number of patients | Number of isolates | Region(city) | Resistance rate (%) | Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AML | TE | MTZ | CLR | LE | RD | |||||||
2008 | E-test | 31 | 31 | West (Bursa) | 3.2 | 3.2 | 41.9 | 41.9 | - | - | 14 | |
2010 | E-test | 149 | 102 | South (Mersin) | 0 | 9.1 | 45.5 | 18.1 | 18.2 | - | 46 | |
2011 | E-test | 344 | 104 | North (Trabzon) | 2.9 | 1 | 31.1 | 28.2 | 34 | - | 27 | |
2013 | E-test | 98 | 98 | West (İstanbul) | 0 | 0 | 35.5 | 36.7 | 29.5 | - | 44 | |
2017 | E-test | 63 | 63 | West (İstanbul) | - | - | - | 38.1 | - | - | 45 | |
This study | E-test | 422 | 133 | West (Bursa) | 0 | 0 | 62 | 19 | 36 | 12 | - |
AML: Amoxicillin, TE: Tetracycline, MTZ: Metronidazole, LE: Levofloxacin, CLR: Clarithromycin, RD: Rifampicin, Ref.: Reference.